FLUOROCHEM:NSEGujarat Fluorochemicals Ltd. Analysis
Data as of 2026-03-16 - not real-time
₹3,078.70
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Technical outlook: The stock is trading below its short‑ and long‑term moving averages, indicating a bearish price trajectory, and the MACD histogram is negative, reinforcing downside momentum. However, the RSI is in the oversold region and volume is increasing, suggesting a potential short‑term bounce toward the identified support level.
Fundamental outlook: Valuation multiples are elevated, with price‑to‑earnings and price‑to‑book ratios well above sector averages, while the balance sheet shows very high leverage, negligible cash generation and zero free cash flow, raising concerns about earnings sustainability. The dividend yield is minimal and the payout ratio, though low, is unlikely to be maintained given cash constraints. Market sentiment: Analyst consensus is bullish with a buy recommendation and a target price that implies notable upside, and the fear‑greed index signals extreme greed, but the underlying financial health tempers that optimism.
Fundamental outlook: Valuation multiples are elevated, with price‑to‑earnings and price‑to‑book ratios well above sector averages, while the balance sheet shows very high leverage, negligible cash generation and zero free cash flow, raising concerns about earnings sustainability. The dividend yield is minimal and the payout ratio, though low, is unlikely to be maintained given cash constraints. Market sentiment: Analyst consensus is bullish with a buy recommendation and a target price that implies notable upside, and the fear‑greed index signals extreme greed, but the underlying financial health tempers that optimism.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish technical trend with price below key moving averages
- Oversold RSI and rising volume hint at limited upside
- Proximity to support level limiting downside risk
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Forward earnings guidance shows strong EPS growth
- Analyst target price suggests material upside
- Improving market sentiment despite valuation concerns
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- High leverage and weak cash generation raise sustainability questions
- Elevated valuation multiples may limit upside
- Sector cyclicality and regulatory exposure add uncertainty
Key Metrics & Analysis
Financial Health
Revenue Growth-1.00%
Profit Margin13.52%
P/E Ratio51.4
Debt/Equity22.48
P/B Ratio4.4
Technical Analysis
TrendBearish
RSI32.8
Support₹2,980.50
Resistance₹3,550.00
MA 20₹3,336.89
MA 50₹3,340.86
MA 200₹3,508.72
MACDBearish
VolumeIncreasing
Fear & Greed Index78.27
Valuation
Target Price₹3,657.31
Upside/Downside18.79%
GradeOvervalued
TypeBlend
Dividend Yield0.10%
Risk Assessment
Beta-0.13
Volatility36.17%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.